[go: up one dir, main page]

CL2017003373A1 - Métodos de modulación de moléculas de vigilancia de adn citosólicas. - Google Patents

Métodos de modulación de moléculas de vigilancia de adn citosólicas.

Info

Publication number
CL2017003373A1
CL2017003373A1 CL2017003373A CL2017003373A CL2017003373A1 CL 2017003373 A1 CL2017003373 A1 CL 2017003373A1 CL 2017003373 A CL2017003373 A CL 2017003373A CL 2017003373 A CL2017003373 A CL 2017003373A CL 2017003373 A1 CL2017003373 A1 CL 2017003373A1
Authority
CL
Chile
Prior art keywords
modulation methods
molecules
cytosolic dna
dna monitoring
monitoring molecules
Prior art date
Application number
CL2017003373A
Other languages
English (en)
Inventor
Thomas Ilg
Albert Abraham
Jason Nickell
Daniel Keil
Christian Weiss
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of CL2017003373A1 publication Critical patent/CL2017003373A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

<p>MÉTODOS PARA GENERAR UNA RESPUESTA INMUNOLÓGICA EN UN SUJETO MEDIANTE LA ACTIVACIÓN DE MOLÉCULAS Y VÍAS DE SEÑALIZACIÓN DE INMUNIDAD INNATA ESPECÍFICAS. EN PARTICULAR, SE USA UNA COMPOSICIÓN INMUNOMODULADORA PARA ESTIMULAR MOLÉCULAS Y VÍAS DE SEÑALIZACIÓN DE INMUNIDAD INNATA.</p>
CL2017003373A 2015-06-26 2017-12-26 Métodos de modulación de moléculas de vigilancia de adn citosólicas. CL2017003373A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562185230P 2015-06-26 2015-06-26

Publications (1)

Publication Number Publication Date
CL2017003373A1 true CL2017003373A1 (es) 2018-06-29

Family

ID=56235815

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003373A CL2017003373A1 (es) 2015-06-26 2017-12-26 Métodos de modulación de moléculas de vigilancia de adn citosólicas.

Country Status (22)

Country Link
US (1) US20190233825A1 (es)
EP (1) EP3313376A2 (es)
JP (1) JP2018518511A (es)
KR (1) KR20180021874A (es)
CN (1) CN108472255A (es)
AR (1) AR105160A1 (es)
AU (1) AU2016282879A1 (es)
BR (1) BR112017028121A2 (es)
CA (1) CA2990526A1 (es)
CL (1) CL2017003373A1 (es)
CR (1) CR20180003A (es)
DO (1) DOP2017000313A (es)
HK (1) HK1256128A1 (es)
IL (1) IL256264A (es)
MX (1) MX2017017141A (es)
PE (1) PE20181208A1 (es)
PH (1) PH12017502413A1 (es)
RU (1) RU2018102915A (es)
SG (1) SG10201913395VA (es)
TW (1) TW201710509A (es)
UY (1) UY36756A (es)
WO (1) WO2016207314A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
PH12019500191A1 (en) 2016-07-26 2022-04-11 Bayer Animal Health Gmbh Increased fertility in bovine species
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US155950A (en) * 1874-10-13 Improvement in hand-saws
EP0772619B2 (en) * 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
DE69838294T2 (de) * 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
CA2423093C (en) * 2000-09-25 2013-09-17 Valentis, Inc. Improved system for regulation of transgene expression
AU2002953015A0 (en) * 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
WO2005033265A2 (en) * 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
MY146351A (en) * 2003-05-29 2012-08-15 Schering Plough Ltd Compositions for treating infection in cattle and swine
ES2684749T3 (es) * 2004-08-13 2018-10-04 The Trustees Of The University Of Pennsylvania Métodos para construir vacunas sin resistencia a antibióticos
US20060135457A1 (en) * 2004-08-13 2006-06-22 Yvonne Paterson Methods for constructing antibiotic resistance free vaccines
PL2429581T3 (pl) * 2009-05-14 2016-01-29 Bayer Ip Gmbh Wzmocniona odpowiedź immunologiczna u gatunków ptaków
LT2654785T (lt) * 2010-12-22 2019-07-10 Bayer Intellectual Property Gmbh Sustiprintas galvijų imuninis atsakas
EP2714907B1 (en) * 2011-05-26 2016-06-15 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
AR091569A1 (es) * 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
WO2015128461A1 (en) * 2014-02-28 2015-09-03 Bayer Animal Health Gmbh Immunostimulatory plasmids

Also Published As

Publication number Publication date
WO2016207314A2 (en) 2016-12-29
UY36756A (es) 2017-01-31
CR20180003A (es) 2018-03-20
US20190233825A1 (en) 2019-08-01
AU2016282879A1 (en) 2018-01-18
SG10201913395VA (en) 2020-03-30
CA2990526A1 (en) 2016-12-29
DOP2017000313A (es) 2018-02-28
MX2017017141A (es) 2018-03-09
PE20181208A1 (es) 2018-07-23
EP3313376A2 (en) 2018-05-02
WO2016207314A3 (en) 2017-02-09
TW201710509A (zh) 2017-03-16
AR105160A1 (es) 2017-09-13
CN108472255A (zh) 2018-08-31
RU2018102915A (ru) 2019-07-29
IL256264A (en) 2018-02-28
HK1256128A1 (zh) 2019-09-13
RU2018102915A3 (es) 2019-12-05
PH12017502413A1 (en) 2018-06-25
BR112017028121A2 (pt) 2018-09-04
KR20180021874A (ko) 2018-03-05
JP2018518511A (ja) 2018-07-12

Similar Documents

Publication Publication Date Title
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
MX2017014136A (es) Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos.
MX393455B (es) Anticuerpos anti-cd40 y sus usos.
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
CO2017004386A2 (es) Fluidos de estimulación de lgn de grado y
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
AR103225A1 (es) Composiciones detergentes, variantes de lipasa y polinucleótidos que las codifican
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX2018012880A (es) Metodos para proporcionar arn de hebra sencilla.
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
AR095774A1 (es) Anticuerpos anti-il-4 y anticuerpos biespecíficos y sus usos
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2016001716A1 (es) Anticuerpo moléculas de tim-3 y usos de los mismos
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
MX375524B (es) Anticuerpos anti-axl.
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
MX376105B (es) Método para producir l-aminoacidos utilizando una bacteria alcalifílica.
CL2017002881A1 (es) Anticuerpos anti-fcrn
EA201691945A1 (ru) Антитела к гемагглютинину вируса гриппа типа b и способы их применения
CY1125447T1 (el) Ειδικες πρωτεινες για baff και b7rp1 και χρησεις αυτων
CL2017003373A1 (es) Métodos de modulación de moléculas de vigilancia de adn citosólicas.
MX378857B (es) Celulas huespedes modificadas y usos de las mismas.
EA201892025A1 (ru) Разделительные текучие среды, способы получения и способы применения
DOP2016000202A (es) Proteínas de fusión uti